Cabaletta Bio, Inc. (CABA)
| Market Cap | 262.80M +15.4% |
| Revenue (ttm) | n/a |
| Net Income | -181.32M |
| EPS | -1.54 |
| Shares Out | 169.55M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,741,616 |
| Open | 1.610 |
| Previous Close | 1.620 |
| Day's Range | 1.520 - 1.625 |
| 52-Week Range | 1.505 - 4.230 |
| Beta | 3.47 |
| Analysts | Buy |
| Price Target | 13.25 (+754.84%) |
| Est. Earnings | Nov 9, 2026 |
About CABA
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company’s lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclero... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for CABA stock is "Buy." The 12-month stock price target is $13.25, which is an increase of 754.84% from the latest price.
News
Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PHILADELPHIA, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies des...
Cabaletta Bio Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Rese-cel, a nine-day autologous CAR T-cell therapy, demonstrates high efficacy and a differentiated safety profile in autoimmune diseases, with no severe neurotoxicity or IEC-HS observed in nearly 100 patients. Durable responses, a scalable manufacturing strategy, and a shift toward preconditioning-free regimens position it as a potential paradigm-shifting therapy.
Cabaletta Bio Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Rese-cel’s nine-day manufacturing process and strong safety profile set it apart in the CAR-T space for autoimmune diseases, with over 90 patients treated and no severe neurotoxicity or IEC-HS events. Key upcoming milestones include pivotal data in scleroderma and myositis, BLA filings, and innovations toward outpatient, preconditioning-free therapy.
Cabaletta Bio to Participate in Upcoming Investor Conferences
PHILADELPHIA, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies de...
Cabaletta Bio reports Q2 EPS (34c), consensus (34c)
“A single infusion of rese-cel has demonstrated the potential to deliver deep, clinical responses after discontinuation of all immunomodulators with up to 1.5 years of follow-up as reported in the…
Cabaletta Bio Earnings release: Q2 2026
Cabaletta Bio released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Cabaletta Bio Quarterly report: Q2 2026
Cabaletta Bio has published its Q2 2026 quarterly earnings report on August 13, 2026.
Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Registrational RESET-Myositis ® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel
Cabaletta Bio Slides: Corporate presentation
Cabaletta Bio has posted slides in relation to its latest quarterly earnings report, which was published on August 12, 2026.
Cabaletta Bio Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Rese-cel shows durable, immunomodulator-free remissions in myositis and strong safety, enabling outpatient dosing and rapid adoption. Regulatory strategy targets BLA submission in 2H 2027, with potential for a priority review voucher and significant non-dilutive capital.
Cabaletta Bio presents new data for rese-cel in autoimmune diseases
Cabaletta Bio (CABA) announced new clinical data and development updates for its cell therapy, rese-cel, across its autoimmune portfolio at the EULAR 2026 Congress. In the RESET-Myositis study, 83% of...
Cabaletta Bio Transcript: Jefferies Global Healthcare Conference 2026
Rese-cel demonstrated durable efficacy and a strong safety profile across multiple autoimmune diseases, with over 80% of myositis patients meeting primary endpoints and no relapses up to 1.5 years. Outpatient administration and automated manufacturing support scalability and payer alignment.
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress
83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registrational primary endpoint; all these patients maintained their response off immunomodulators through late...
Cabaletta Bio Slides: Corporate presentation
Cabaletta Bio has posted slides in relation to its latest quarterly earnings report, which was published on June 3, 2026.
Cabaletta Bio Proxy statement: Proxy filing
Cabaletta Bio filed a proxy statement on June 1, 2026, providing details for shareholder voting and corporate governance matters.
Cabaletta Bio Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
Transformative results in autoimmune disease have driven innovation in autologous CAR T, with advances in automated manufacturing and product design enabling scalable, outpatient treatment. Early data show strong efficacy without preconditioning, and strategic partnerships and talent acquisition position the company for leadership in the field.
Cabaletta Bio presents new clinical data for rese-cel
Cabaletta Bio (CABA) announced new clinical and translational data from the first four patients in the lowest dose cohort in RESET-PV evaluating preconditioning-free rese-cel and initial manufacturing...
Cabaletta Bio reports Q1 EPS (39c), consensus (39c)
“Since January, while advancing our myositis pivotal trial and planning to initiate a second pivotal indication, we announced that we have signed a long-term commercial supply agreement with Cellares ...
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV ® study presented today at ASGCT 2026 Annual Meeting along with initial ...
Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting
A single infusion of the lowest dose of rese-cel administered without preconditioning, after discontinuation of all immunomodulators, demonstrated compelling drug-free responses for 6 months in 2 of 4...
Cabaletta Bio Quarterly report: Q1 2026
Cabaletta Bio has published its Q1 2026 quarterly earnings report on May 14, 2026.
Cabaletta Bio Earnings release: Q1 2026
Cabaletta Bio released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Cabaletta Bio Slides: Corporate presentation
Cabaletta Bio has posted slides in relation to its latest quarterly earnings report, which was published on May 14, 2026.
Cabaletta Bio financing overhang concerns should be addressed, says Cantor
Cabaletta Bio (CABA) provided updates for CABA-201, saying that two out of four pemphigus vulgaris patients treated with CABA-201 without preconditioning chemo achieved virtually complete and durable ...
Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering
PHILADELPHIA, May 04, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching curative ta...